drugset
drugset / Trial / NCT03137160

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

NCT03137160 ↗

Phase 2 Completed 4 enrolled Ohio State University Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Timeline

Start
2017-05-04
Primary completion
2018-08-16
Completion
2018-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody — Other

Indications

pyoderma gangrenosum